Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Department of Gastroenterology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Anticancer Agents Med Chem. 2024;24(18):1305-1326. doi: 10.2174/0118715206323900240807110122.
Colorectal cancer is a common malignant tumor with high morbidity and mortality rates, imposing a huge burden on both patients and the healthcare system. Traditional treatments such as surgery, chemotherapy and radiotherapy have limitations, so finding more effective diagnostic and therapeutic tools is critical to improving the survival and quality of life of colorectal cancer patients. While current tumor targeting research mainly focuses on exploring the function and mechanism of molecular targets and screening for excellent drug targets, it is crucial to test the efficacy and mechanism of tumor cell therapy that targets these molecular targets. Selecting the appropriate drug carrier is a key step in effectively targeting tumor cells. In recent years, nanoparticles have gained significant interest as gene carriers in the field of colorectal cancer diagnosis and treatment due to their low toxicity and high protective properties. Nanoparticles, synthesized from natural or polymeric materials, are NM-sized particles that offer advantages such as low toxicity, slow release, and protection of target genes during delivery. By modifying nanoparticles, they can be targeted towards specific cells for efficient and safe targeting of tumor cells. Numerous studies have demonstrated the safety, efficiency, and specificity of nanoparticles in targeting tumor cells, making them a promising gene carrier for experimental and clinical studies. This paper aims to review the current application of nanoparticles in colorectal cancer diagnosis and treatment to provide insights for targeted therapy for colorectal cancer while also highlighting future prospects for nanoparticle development.
结直肠癌是一种常见的恶性肿瘤,发病率和死亡率都很高,给患者和医疗体系都带来了巨大的负担。传统的治疗方法,如手术、化疗和放疗,都存在一定的局限性,因此寻找更有效的诊断和治疗工具对于提高结直肠癌患者的生存率和生活质量至关重要。虽然目前的肿瘤靶向研究主要集中在探索分子靶点的功能和机制以及筛选优秀的药物靶点上,但测试针对这些分子靶点的肿瘤细胞治疗的疗效和机制也同样重要。选择合适的药物载体是有效靶向肿瘤细胞的关键步骤。近年来,由于纳米粒子具有低毒性和高保护性能,因此作为基因载体在结直肠癌的诊断和治疗领域引起了广泛关注。纳米粒子是由天然或聚合材料合成的 NM 大小的颗粒,具有低毒性、缓慢释放和在传递过程中保护靶基因等优点。通过修饰纳米粒子,可以将其靶向特定的细胞,从而实现对肿瘤细胞的高效和安全靶向。许多研究已经证明了纳米粒子在靶向肿瘤细胞方面的安全性、效率和特异性,使其成为实验和临床研究中很有前途的基因载体。本文旨在综述纳米粒子在结直肠癌诊断和治疗中的应用,为结直肠癌的靶向治疗提供思路,同时也强调了纳米粒子发展的未来前景。
Anticancer Agents Med Chem. 2024
Eur J Pharm Biopharm. 2015-6
J Nanobiotechnology. 2024-7-19
Int J Nanomedicine. 2024
Curr Drug Deliv. 2016
Signal Transduct Target Ther. 2023-11-3
Int J Mol Sci. 2023-10-20
J Nanobiotechnology. 2023-10-2
Nanomaterials (Basel). 2023-9-15